Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cell-free supernatant of Clostridium leptum
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Cell-free supernatant of Clostridium leptum (ClCFS) is an experimental biologic therapeutic being investigated for its anti-cancer properties, particularly in breast cancer. [1, 2] It is a complex mixture containing metabolites and soluble factors produced by *Clostridium leptum*, a butyrate-producing anaerobic bacterium that is part of the healthy human gut microbiota. [1, 10] Research suggests that ClCFS inhibits the proliferation of breast cancer cells by inducing apoptosis (programmed cell death). [1, 2] Untargeted metabolomics has identified acetylcarnitine as a potentially key bioactive metabolite. [2] Network pharmacological analysis predicted that its anti-cancer effects may be mediated through core targets including STAT3, IL-1β, BCL2, CASP3, and ESR1. [2] The product is in the preclinical stage of research, and no specific developing company or brand name has been identified. [2]
02
Targets
BCL-2 (BCL-2 family)CASP3 (Caspase-3)ESR1 (ERα)IL1B (Interleukin-1 beta)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on cell-free supernatant of Clostridium leptum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cell-free supernatant of Clostridium leptum.